statistiche ricercatore

Continente	#
AS - Asia	389
EU - Europa	388
NA - Nord America	321
SA - Sud America	37
AF - Africa	12
Continente sconosciuto - Info sul continente non disponibili	2
OC - Oceania	2
Totale	1.151

Nazione	#
US - Stati Uniti d'America	307
IT - Italia	143
CN - Cina	123
SG - Singapore	84
DE - Germania	76
HK - Hong Kong	53
IN - India	34
BR - Brasile	30
VN - Vietnam	29
FR - Francia	27
NL - Olanda	25
GB - Regno Unito	23
SE - Svezia	23
RU - Federazione Russa	19
TR - Turchia	18
FI - Finlandia	17
JP - Giappone	15
PL - Polonia	12
CI - Costa d'Avorio	7
BD - Bangladesh	6
CA - Canada	6
IE - Irlanda	5
PH - Filippine	5
TW - Taiwan	5
ES - Italia	4
KR - Corea	4
MX - Messico	3
AP - ???statistics.table.value.countryCode.AP???	2
AR - Argentina	2
AT - Austria	2
CH - Svizzera	2
CL - Cile	2
HU - Ungheria	2
ID - Indonesia	2
IQ - Iraq	2
MA - Marocco	2
UZ - Uzbekistan	2
AU - Australia	1
BE - Belgio	1
CO - Colombia	1
CZ - Repubblica Ceca	1
EG - Egitto	1
GR - Grecia	1
IL - Israele	1
IR - Iran	1
JM - Giamaica	1
KE - Kenya	1
LV - Lettonia	1
MK - Macedonia	1
MV - Maldive	1
NI - Nicaragua	1
NZ - Nuova Zelanda	1
PA - Panama	1
PK - Pakistan	1
PS - Palestinian Territory	1
PT - Portogallo	1
PY - Paraguay	1
RO - Romania	1
SA - Arabia Saudita	1
SV - El Salvador	1
TH - Thailandia	1
TN - Tunisia	1
TT - Trinidad e Tobago	1
UA - Ucraina	1
VE - Venezuela	1
Totale	1.151

Nome	#
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)	514
Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational multicenter Italian PALMARES study	178
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors	160
Efficacy and safety of direct oral anticoagulants in the pediatric population: a systematic review and a meta-analysis	123
Poly (ADP-ribose) polymerase inhibitors in solid tumours : Systematic review and meta-analysis	108
Early Changes of the Standardized Uptake Values (SUVmax) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer	106
null	3
Abstract HER2-02: HER2-02 HER2-Low Status is Associated with Worse Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Patients Treated With First-Line Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy	1
Totale	1.193

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	40	0	0	0	0	0	0	0	0	0	0	13	27
2021/2022	189	22	29	18	18	17	16	8	14	17	12	7	11
2022/2023	67	8	7	5	3	11	12	2	2	7	1	6	3
2023/2024	118	4	3	6	6	21	2	15	14	5	10	19	13
2024/2025	255	10	24	16	17	15	8	9	21	16	27	37	55
2025/2026	522	53	64	91	44	39	21	75	6	46	44	39	0
Totale													1.193

IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca